TSE:3407Chemicals
Asahi Kasei Expands Pharma Reach With Aicuris Deal And AK1940 Trial
Asahi Kasei (TSE:3407) has completed its acquisition of German biopharmaceutical company Aicuris Anti-infective Cures.
The company has also initiated a Phase I clinical trial for AK1940, a new therapy candidate for autoimmune diseases.
Both developments mark a shift in focus toward infectious and autoimmune disease treatments within Asahi Kasei's pharmaceutical operations.
Asahi Kasei, traditionally known for chemicals, materials, and health care businesses, is steadily building out its...